drugset / Trial / NCT01143272
Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea
Phase 3
Terminated
477 enrolled
Bernhard Nocht Institute for Tropical Medicine
German Federal Ministry of Education and Research · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
When patients in hospitals receive antibiotics they often develop diarrhoea. The consequences may be grave for the patient. Thus far, no preventive measure is available. The investigators hypothesize that the apathogenic yeast Saccharomyces boulardii, administered in addition to the antibiotic, may prevent episodes of diarrhoea or may lead to less pronounced diarrhoea. To test this hypothesis, the investigators are carrying out a clinical trial in 1520 adult patients in several hospitals.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Saccharomyces boulardii | Other / unclassified | 250 mg | Oral |